Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences August 1, 2024 Christopher G Witowski, Mika R Hess, Nate T Jones et al. 7 citations
A transdermal patch for delivering N,N-dimethyltryptamine (DMT) at low, non-hallucinogenic doses was developed and tested in mice. The patch provided consistent, extended drug release, achieving plasma levels below 60 ng/mL. Compared to intravenous administration, the patch extended DMT's half-life by 20-fold and achieved 77% bioavailability. Female and male mice showed notable differences during IV dosing, but transdermal delivery produced steady levels. A head twitch assay indicated no hallucinogenic effects at these low plasma concentrations. The patch could offer a non-invasive, outpatient treatment option for conditions where high, bolus doses are unnecessary.